New Drug Indication Approval - Jan 2020
|
Product Name
|
KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL AND 160MG/VIAL |
|
Active Ingredient
|
Trastuzumab emtansine |
|
Product Registrant
|
ROCHE SINGAPORE PTE LTD
|
|
Date of Approval
|
14/01/2020 |
|
Indications:
Early Breast Cancer (EBC)
Kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease, after pre-operative systemic treatment.
|
|
Product Name
|
ADCETRIS POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL
|
|
Active Ingredient
|
Brentuximab vedotin |
|
Product Registrant
|
TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.
|
|
Date of Approval
|
16/01/2020 |
|
Indications:
Previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy
Adcetris is indicated for the frontline treatment of adult patients with previously untreated CD30+ advanced cHL in combination with doxorubicin, vinblastine and dacarbazine (AVD). |
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Indication Approvals